MGAT3

Across TCGA pan-cancer cohorts, MGAT3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MGAT3 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MGAT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MGAT3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THYM, BRCA, and COAD are the cancer types where MGAT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BRCA	DFS	Median	All	0.217	0.903	<.001	24	view →
COAD	OS	Median	IV	0.045	0.659	<.001	13	view →
SARC	DFS	Median	All	0.150	0.614	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.669	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MGAT3–THYM (OS)

Open the THYM breakdown →